Momordica charantia leaf extract suppresses rat prostate cancer progression in vitro and in vivo

Cancer Science

Volumn 101, Issue 10, 2010, Pages 2234-2240

  Pitchakarn, Pornsiri ^a,b   Ogawa, Kumiko ^a,c   Suzuki, Shugo ^a   Takahashi, Satoru ^a   Asamoto, Makoto ^a   Chewonarin, Teera ^b   Limtrakul, Pornngarm ^b   Shirai, Tomoyuki ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b Faculty of Medicine Chiang Mai University   (Thailand)

^c NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; COLLAGENASE; GELATINASE; GELATINASE A; GELATINASE B; MESSENGER RNA; MOMORDICA CHARANTIA EXTRACT; UROKINASE; PLANT EXTRACT; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CELL INVASION; CONTROLLED STUDY; DRUG INHIBITION; ENZYME RELEASE; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; LUNG METASTASIS; MALE; MOMORDICA CHARANTIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; ZYMOGRAPHY; ANIMAL; DISEASE COURSE; ENZYMOLOGY; GENETICS; LUNG TUMOR; PATHOLOGY; PHYSIOLOGY; PHYTOTHERAPY; PLANT LEAF; PROSTATIC NEOPLASMS; RAT; SECONDARY; SECRETION (PROCESS); TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DISEASE PROGRESSION; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MOMORDICA CHARANTIA; PHYTOTHERAPY; PLANT EXTRACTS; PLANT LEAVES; PROSTATIC NEOPLASMS; RATS; TRANSFORMING GROWTH FACTOR BETA;

EID: 77957037371     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01669.x     Document Type: Article

References (55)

1. Gronberg H. Prostate cancer epidemiology. Lancet 2003, 361:859-64.
2. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977, 197:893-5.
3. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999, 274:21491-4.
4. Braun-Falco M, Holtmann C, Lordick F, Ring J. Follicular drug reaction from cetuximab: a common side effect in the treatment of metastatic colon carcinoma. Hautarzt 2006, 57:701-4.
5. Yodkeeree S, Garbisa S, Limtrakul P. Tetrahydrocurcumin inhibits HT1080 cell migration and invasion via downregulation of MMPs and uPA. Acta Pharmacol Sin 2008, 29:853-60.
6. Lin SS, Lai KC, Hsu SC. Curcumin inhibits the migration and invasion of human A549 lung cancer cells through the inhibition of matrix metalloproteinase-2 and -9 and Vascular Endothelial Growth Factor (VEGF). Cancer Lett 2009, 285:127-33.
7. Giron LM, Freire V, Alonzo A, Caceres A. Ethnobotanical survey of the medicinal flora used by the Caribs of Guatemala. J Ethnopharmacol 1991, 34:173-87.
8. Lans C, Brown G. Observations on ethnoveterinary medicines in Trinidad and Tobago. Prev Vet Med 1998, 35:125-42.
9. Licastro F, Franceschi C, Barbieri L, Stirpe F. Toxicity of Momordica charantia lectin and inhibitor for human normal and leukaemic lymphocytes. Virchows Arch B Cell Pathol Incl Mol Pathol 1980, 33:257-65.
10. Ng TB, Liu WK, Sze SF, Yeung HW. Action of alpha-momorcharin, a ribosome inactivating protein, on cultured tumor cell lines. Gen Pharmacol 1994, 25:75-7.
11. Battelli MG, Polito L, Bolognesi A, Lafleur L, Fradet Y, Stirpe F. Toxicity of ribosome-inactivating proteins-containing immunotoxins to a human bladder carcinoma cell line. Int J Cancer 1996, 65:485-90.
12. Ganguly C, De S, Das S. Prevention of carcinogen-induced mouse skin papilloma by whole fruit aqueous extract of Momordica charantia. Eur J Cancer Prev 2000, 9:283-8.
13. Sun Y, Huang PL, Li JJ, Huang YQ, Zhang L, Lee-Huang S. Anti-HIV agent MAP30 modulates the expression profile of viral and cellular genes for proliferation and apoptosis in AIDS-related lymphoma cells infected with Kaposi's sarcoma-associated virus. Biochem Biophys Res Commun 2001, 287:983-94.
14. Basch E, Gabardi S, Ulbricht C. Bitter melon (Momordica charantia): a review of efficacy and safety. Am J Health Syst Pharm 2003, 60:356-9.
15. Shi H, Hiramatsu M, Komatsu M, Kayama T. Antioxidant property of Fructus Momordicae extract. Biochem Mol Biol Int 1996, 40:1111-21.
16. Lee-Huang S, Huang PL, Chen HC, Bourinbaiar A, Huang HI, Kung HF. Anti-HIV and anti-tumor activities of recombinant MAP30 from bitter melon. Gene 1995, 161:151-6.
17. Tan MJ, Ye JM, Turner N. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem Biol 2008, 15:263-73.
18. Cunnick JE, Sakamoto K, Chapes SK, Fortner GW, Takemoto DJ. Induction of tumor cytotoxic immune cells using a protein from the bitter melon (Momordica charantia). Cell Immunol 1990, 126:278-89.
19. Kusamran WR, Ratanavila A, Tepsuwan A. Effects of neem flowers, Thai and Chinese bitter gourd fruits and sweet basil leaves on hepatic monooxygenases and glutathione S-transferase activities, and in vitro metabolic activation of chemical carcinogens in rats. Food Chem Toxicol 1998, 36:475-84.
20. Limtrakul P, Khantamat O, Pintha K. Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract. Cancer Chemother Pharmacol 2004, 54:525-30.
21. Nakanishi H, Takeuchi S, Kato K. Establishment and characterization of three androgen-independent, metastatic carcinoma cell lines from 3,2'-dimethyl-4-aminobiphenyl-induced prostatic tumors in F344 rats. Jpn J Cancer Res 1996, 87:1218-26.
22. Hamasaki K, Kogure K, Ohwada K. A biological method for the quantitative measurement of tetrodotoxin (TTX): tissue culture bioassay in combination with a water-soluble tetrazolium salt. Toxicon 1996, 34:490-5.
23. Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 1999, 85:906-11.
24. Law B, Hsiao JK, Bugge TH, Weissleder R, Tung CH. Optical zymography for specific detection of urokinase plasminogen activator activity in biological samples. Anal Biochem 2005, 338:151-8.
25. Platel K, Shurpalekar KS, Srinivasan K. Influence of bitter gourd (Momordica charantia) on growth and blood constituents in albino rats. Nahrung 1993, 37:156-60.
26. Virdi J, Sivakami S, Shahani S, Suthar AC, Banavalikar MM, Biyani MK. Antihyperglycemic effects of three extracts from Momordica charantia. J Ethnopharmacol 2003, 88:107-11.
27. Subratty AH, Gurib-Fakim A, Mahomoodally F. Bitter melon: an exotic vegetable with medicinal values. Nutr Food Sci 2005, 35:143-7.
28. Liotta LA, Rao CN, Wewer UM. Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem 1986, 55:1037-57.
29. Gilles C, Polette M, Seiki M, Birembaut P, Thompson EW. Implication of collagen type I-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma. Lab Invest 1997, 76:651-60.
30. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999, 13:781-92.
31. Zeng ZS, Cohen AM, Guillem JG. Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis 1999, 20:749-55.
32. Stetler-Stevenson WG. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 1990, 9:289-303.
33. Wang M, Wang T, Liu S, Yoshida D, Teramoto A. The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathol 2003, 20:65-72.
34. Papathoma AS, Zoumpourlis V, Balmain A, Pintzas A. Role of matrix metalloproteinase-9 in progression of mouse skin carcinogenesis. Mol Carcinog 2001, 31:74-82.
35. Cockett MI, Murphy G, Birch ML. Matrix metalloproteinases and metastatic cancer. Biochem Soc Symp 1998, 63:295-313.
36. Li Y, Cozzi PJ. Targeting uPA/uPAR in prostate cancer. Cancer Treat Rev 2007, 33:521-7.
37. Pulukuri SM, Gondi CS, Lakka SS. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 2005, 280:36529-40.
38. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006, 69:562-73.
39. Fisher JF, Mobashery S. Recent advances in MMP inhibitor design. Cancer Metastasis Rev 2006, 25:115-36.
40. Nakano A, Tani E, Miyazaki K, Yamamoto Y, Furuyama J. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J Neurosurg 1995, 83:298-307.
41. George SJ, Baker AH, Angelini GD, Newby AC. Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. Gene Ther 1998, 5:1552-60.
42. Stearns ME, Garcia FU, Fudge K, Rhim J, Wang M. Role of interleukin 10 and transforming growth factor beta1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. Clin Cancer Res 1999, 5:711-20.
43. Konrad L, Scheiber JA, Schwarz L, Schrader AJ, Hofmann R. TGF-beta1 and TGF-beta2 strongly enhance the secretion of plasminogen activator inhibitor-1 and matrix metalloproteinase-9 of the human prostate cancer cell line PC-3. Regul Pept 2009, 155:28-32.
44. Matthews E, Yang T, Janulis L. Down-regulation of TGF-beta1 production restores immunogenicity in prostate cancer cells. Br J Cancer 2000, 83:519-25.
45. Manabe M, Takenaka R, Nakasa T, Okinaka O. Induction of anti-inflammatory responses by dietary Momordica charantia L. (bitter gourd). Biosci Biotechnol Biochem 2003, 67:2512-7.
46. Yamashita S, Takahashi S, McDonell N. Methylation silencing of transforming growth factor-beta receptor type II in rat prostate cancers. Cancer Res 2008, 68:2112-21.
47. Lavhale MS, Kumar S, Mishra SH, Sitasawad SL. A novel triterpenoid isolated from the root bark of Ailanthus excelsa Roxb (Tree of Heaven), AECHL-1 as a potential anti-cancer agent. PLoS ONE 2009, 4:53-65.
48. Sun C, Zhang M, Shan X. Inhibitory effect of cucurbitacin E on pancreatic cancer cells growth via STAT3 signaling. J Cancer Res Clin Oncol 2010, 136:603-10.
49. Yasuda S, Yogosawa S, Izutani Y, Nakamura Y, Watanabe H, Sakai T. Cucurbitacin B induces G(2) arrest and apoptosis via a reactive oxygen species-dependent mechanism in human colon adenocarcinoma SW480 cells. Mol Nutr Food Res 2010, 54:559-65.
50. Yanamandra N, Berhow MA, Konduri S. Triterpenoids from Glycine max decrease invasiveness and induce caspase-mediated cell death in human SNB19 glioma cells. Clin Exp Metastasis 2003, 20:375-83.
51. Weng CJ, Chau CF, Chen KD, Chen DH, Yen GC. The anti-invasive effect of lucidenic acids isolated from a new Ganoderma lucidum strain. Mol Nutr Food Res 2007, 51:1472-7.
52. Zhang M, Hettiarachchy NS, Horax R, Chen P, Over KF. Effect of maturity stages and drying methods on the retention of selected nutrients and phytochemicals in bitter melon (Momordica charantia) leaf. J Food Sci 2009, 74:C441-8.
53. Lin JP, Yang JS, Lu CC. Rutin inhibits the proliferation of murine leukemia WEHI-3 cells in vivo and promotes immune response in vivo. Leuk Res 2009, 33:823-8.
54. Luo H, Jiang BH, King SM, Chen YC. Inhibition of cell growth and VEGF expression in ovarian cancer cells by flavonoids. Nutr Cancer 2008, 60:800-9.
55. Martinez Conesa C, Vicente Ortega V, Yanez Gascon MJ. Treatment of metastatic melanoma B16F10 by the flavonoids tangeretin, rutin, and diosmin. J Agric Food Chem 2005, 53:6791-7.